share_log

Maxim Group Upgrades Vistagen Therapeutics to Buy, Announces $30 Price Target

Benzinga ·  Aug 8, 2023 07:09

Maxim Group analyst Jason McCarthy upgrades Vistagen Therapeutics (NASDAQ:VTGN) from Hold to Buy and announces $30 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment